In this interview, two experts in the field of acute myeloid leukaemia (AML), Jean-Baptiste Micol, University of Paris-Saclay, France, and Thomas Cluzeau, University Hospital of Nice, France, share their views and debate the current landscape of real-world data in AML research and treatment.
EMJ Hematology 9 [Supplement 5] . 2021
Latest articlesAll articles
Extension Treatment: Preventing Recurrence of Venous Thromboembolism
VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), affects approximately 1–2 in every 1,000 people annually.2 It is a major cause of death and disability in England, with thousands of deaths directly attributed to the condition each year.
Infographic: Differences in Mechanism of Action and Selectivity of Covalent and Non-Covalent BTK Inhibitors
Infographic: Differences in Mechanism of Action and Selectivity of Covalent and Non-Covalent BTK Inhibitors. Provided by Clinical Care Options, LLC. Supported by an educational grant from Lilly.
Infographic: Perceptions of Treatments in AML – A Survey of 375 European Haematologists
Acute myeloid leukaemia (AML) is a rapidly progressing haematological cancer with a poor prognosis. This infographic summarises the key results from an online survey conducted in 2022 on the perceptions of AML treatments among clinicians in Europe. Haematologists and oncologists from five European countries were asked their opinions on topics such as first-line treatments, the intensity of treatment regimens, and therapies for curative intent for patients with AML.